These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30190590)

  • 1. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate.
    Matyskiela ME; Couto S; Zheng X; Lu G; Hui J; Stamp K; Drew C; Ren Y; Wang M; Carpenter A; Lee CW; Clayton T; Fang W; Lu CC; Riley M; Abdubek P; Blease K; Hartke J; Kumar G; Vessey R; Rolfe M; Hamann LG; Chamberlain PP
    Nat Chem Biol; 2018 Oct; 14(10):981-987. PubMed ID: 30190590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.
    Donovan KA; An J; Nowak RP; Yuan JC; Fink EC; Berry BC; Ebert BL; Fischer ES
    Elife; 2018 Aug; 7():. PubMed ID: 30067223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex.
    Matyskiela ME; Clayton T; Zheng X; Mayne C; Tran E; Carpenter A; Pagarigan B; McDonald J; Rolfe M; Hamann LG; Lu G; Chamberlain PP
    Nat Struct Mol Biol; 2020 Apr; 27(4):319-322. PubMed ID: 32251415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide and its metabolite 5-hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF.
    Yamanaka S; Murai H; Saito D; Abe G; Tokunaga E; Iwasaki T; Takahashi H; Takeda H; Suzuki T; Shibata N; Tamura K; Sawasaki T
    EMBO J; 2021 Feb; 40(4):e105375. PubMed ID: 33470442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and biophysical comparisons of the pomalidomide- and CC-220-induced interactions of SALL4 with cereblon.
    Ma X; Leon B; Ornelas E; Dovala D; Tandeske L; Luu C; Pardee G; Widger S; Solomon JM; Beckwith REJ; Moser H; Clifton MC; Wartchow CA
    Sci Rep; 2023 Dec; 13(1):22088. PubMed ID: 38086859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.
    Belair DG; Lu G; Waller LE; Gustin JA; Collins ND; Kolaja KL
    Sci Rep; 2020 Feb; 10(1):2864. PubMed ID: 32071327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
    Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
    Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering the mystery of thalidomide teratogenicity.
    Ito T; Handa H
    Congenit Anom (Kyoto); 2012 Mar; 52(1):1-7. PubMed ID: 22348778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a primary target of thalidomide teratogenicity.
    Ito T; Ando H; Suzuki T; Ogura T; Hotta K; Imamura Y; Yamaguchi Y; Handa H
    Science; 2010 Mar; 327(5971):1345-50. PubMed ID: 20223979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teratogenic effects of thalidomide: molecular mechanisms.
    Ito T; Ando H; Handa H
    Cell Mol Life Sci; 2011 May; 68(9):1569-79. PubMed ID: 21207098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The teratogenic effects of thalidomide on limbs.
    Vargesson N
    J Hand Surg Eur Vol; 2019 Jan; 44(1):88-95. PubMed ID: 30335598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SALL4 mutations in Okihiro syndrome (Duane-radial ray syndrome), acro-renal-ocular syndrome, and related disorders.
    Kohlhase J; Chitayat D; Kotzot D; Ceylaner S; Froster UG; Fuchs S; Montgomery T; Rösler B
    Hum Mutat; 2005 Sep; 26(3):176-83. PubMed ID: 16086360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative Role of the SALL4 Gene: From Thalidomide Embryopathy to Genetic Defects of the Upper Limb, Internal Organs, Cerebral Midline, and Pituitary.
    Kodytková A; Dušátková P; Amaratunga SA; Plachý L; Průhová Š; Lebl J
    Horm Res Paediatr; 2024; 97(2):106-112. PubMed ID: 37285827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide.
    Furihata H; Yamanaka S; Honda T; Miyauchi Y; Asano A; Shibata N; Tanokura M; Sawasaki T; Miyakawa T
    Nat Commun; 2020 Sep; 11(1):4578. PubMed ID: 32929090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
    Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG
    Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, acro-renal-ocular syndrome, and patients previously reported to represent thalidomide embryopathy.
    Kohlhase J; Schubert L; Liebers M; Rauch A; Becker K; Mohammed SN; Newbury-Ecob R; Reardon W
    J Med Genet; 2003 Jul; 40(7):473-8. PubMed ID: 12843316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury.
    Lecca D; Hsueh SC; Luo W; Tweedie D; Kim DS; Baig AM; Vargesson N; Kim YK; Hwang I; Kim S; Hoffer BJ; Chiang YH; Greig NH
    J Biomed Sci; 2023 Mar; 30(1):16. PubMed ID: 36872339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cereblon modulators: Low molecular weight inducers of protein degradation.
    Chamberlain PP; Cathers BE
    Drug Discov Today Technol; 2019 Apr; 31():29-34. PubMed ID: 31200856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
    Boichenko I; Deiss S; Bär K; Hartmann MD; Hernandez Alvarez B
    J Med Chem; 2016 Jan; 59(2):770-4. PubMed ID: 26730808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thalidomide teratogenicity and its direct target identification].
    Ito T; Ando H; Handa H
    Nihon Rinsho; 2015 Jan; 73(1):143-8. PubMed ID: 25626320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.